Cargando…
Case report: Acute exacerbation of interstitial pneumonia related to messenger RNA COVID-19 vaccination
Messenger RNA (mRNA) vaccines that protect against COVID-19 are widely used in many countries owing to their high efficacy and safety profiles. Recently, few severe adverse events, such as anaphylaxis and myocarditis, were reported in healthy individuals. The safety of mRNA COVID-19 vaccines has not...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8769663/ https://www.ncbi.nlm.nih.gov/pubmed/35065256 http://dx.doi.org/10.1016/j.ijid.2022.01.031 |
_version_ | 1784635200166166528 |
---|---|
author | Amiya, Saori Fujimoto, Jun Matsumoto, Kinnosuke Yamamoto, Makoto Yamamoto, Yuji Yoneda, Midori Kuge, Tomoki Miyake, Kotaro Shiroyama, Takayuki Hirata, Haruhiko Takeda, Yoshito Kumanogoh, Atsushi |
author_facet | Amiya, Saori Fujimoto, Jun Matsumoto, Kinnosuke Yamamoto, Makoto Yamamoto, Yuji Yoneda, Midori Kuge, Tomoki Miyake, Kotaro Shiroyama, Takayuki Hirata, Haruhiko Takeda, Yoshito Kumanogoh, Atsushi |
author_sort | Amiya, Saori |
collection | PubMed |
description | Messenger RNA (mRNA) vaccines that protect against COVID-19 are widely used in many countries owing to their high efficacy and safety profiles. Recently, few severe adverse events, such as anaphylaxis and myocarditis, were reported in healthy individuals. The safety of mRNA COVID-19 vaccines has not been adequately studied in patients with interstitial lung disease. We report 2 cases of acute exacerbation of preexisting interstitial pneumonia associated with mRNA COVID-19 vaccination. In both cases, lung disease was stable before the vaccination. Initial responses to steroid therapy were unfavorable, and intravenous cyclophosphamide was administered in both cases. Both patients were diagnosed with vaccine-related exacerbation of interstitial pneumonia based on laboratory results, radiologic features, and the observed clinical course, which lacked other causative events. We suggest that clinicians should note the possibility of acute exacerbation of pneumonia after mRNA COVID-19 vaccination and carefully monitor patients with interstitial lung disease. |
format | Online Article Text |
id | pubmed-8769663 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. |
record_format | MEDLINE/PubMed |
spelling | pubmed-87696632022-01-20 Case report: Acute exacerbation of interstitial pneumonia related to messenger RNA COVID-19 vaccination Amiya, Saori Fujimoto, Jun Matsumoto, Kinnosuke Yamamoto, Makoto Yamamoto, Yuji Yoneda, Midori Kuge, Tomoki Miyake, Kotaro Shiroyama, Takayuki Hirata, Haruhiko Takeda, Yoshito Kumanogoh, Atsushi Int J Infect Dis Case Report Messenger RNA (mRNA) vaccines that protect against COVID-19 are widely used in many countries owing to their high efficacy and safety profiles. Recently, few severe adverse events, such as anaphylaxis and myocarditis, were reported in healthy individuals. The safety of mRNA COVID-19 vaccines has not been adequately studied in patients with interstitial lung disease. We report 2 cases of acute exacerbation of preexisting interstitial pneumonia associated with mRNA COVID-19 vaccination. In both cases, lung disease was stable before the vaccination. Initial responses to steroid therapy were unfavorable, and intravenous cyclophosphamide was administered in both cases. Both patients were diagnosed with vaccine-related exacerbation of interstitial pneumonia based on laboratory results, radiologic features, and the observed clinical course, which lacked other causative events. We suggest that clinicians should note the possibility of acute exacerbation of pneumonia after mRNA COVID-19 vaccination and carefully monitor patients with interstitial lung disease. The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2022-03 2022-01-19 /pmc/articles/PMC8769663/ /pubmed/35065256 http://dx.doi.org/10.1016/j.ijid.2022.01.031 Text en © 2022 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Case Report Amiya, Saori Fujimoto, Jun Matsumoto, Kinnosuke Yamamoto, Makoto Yamamoto, Yuji Yoneda, Midori Kuge, Tomoki Miyake, Kotaro Shiroyama, Takayuki Hirata, Haruhiko Takeda, Yoshito Kumanogoh, Atsushi Case report: Acute exacerbation of interstitial pneumonia related to messenger RNA COVID-19 vaccination |
title | Case report: Acute exacerbation of interstitial pneumonia related to messenger RNA COVID-19 vaccination |
title_full | Case report: Acute exacerbation of interstitial pneumonia related to messenger RNA COVID-19 vaccination |
title_fullStr | Case report: Acute exacerbation of interstitial pneumonia related to messenger RNA COVID-19 vaccination |
title_full_unstemmed | Case report: Acute exacerbation of interstitial pneumonia related to messenger RNA COVID-19 vaccination |
title_short | Case report: Acute exacerbation of interstitial pneumonia related to messenger RNA COVID-19 vaccination |
title_sort | case report: acute exacerbation of interstitial pneumonia related to messenger rna covid-19 vaccination |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8769663/ https://www.ncbi.nlm.nih.gov/pubmed/35065256 http://dx.doi.org/10.1016/j.ijid.2022.01.031 |
work_keys_str_mv | AT amiyasaori casereportacuteexacerbationofinterstitialpneumoniarelatedtomessengerrnacovid19vaccination AT fujimotojun casereportacuteexacerbationofinterstitialpneumoniarelatedtomessengerrnacovid19vaccination AT matsumotokinnosuke casereportacuteexacerbationofinterstitialpneumoniarelatedtomessengerrnacovid19vaccination AT yamamotomakoto casereportacuteexacerbationofinterstitialpneumoniarelatedtomessengerrnacovid19vaccination AT yamamotoyuji casereportacuteexacerbationofinterstitialpneumoniarelatedtomessengerrnacovid19vaccination AT yonedamidori casereportacuteexacerbationofinterstitialpneumoniarelatedtomessengerrnacovid19vaccination AT kugetomoki casereportacuteexacerbationofinterstitialpneumoniarelatedtomessengerrnacovid19vaccination AT miyakekotaro casereportacuteexacerbationofinterstitialpneumoniarelatedtomessengerrnacovid19vaccination AT shiroyamatakayuki casereportacuteexacerbationofinterstitialpneumoniarelatedtomessengerrnacovid19vaccination AT hirataharuhiko casereportacuteexacerbationofinterstitialpneumoniarelatedtomessengerrnacovid19vaccination AT takedayoshito casereportacuteexacerbationofinterstitialpneumoniarelatedtomessengerrnacovid19vaccination AT kumanogohatsushi casereportacuteexacerbationofinterstitialpneumoniarelatedtomessengerrnacovid19vaccination |